CytomX Therapeutics, Inc. – Value Analysis (NASDAQ:CTMX) : December 27, 2016

Capitalcube gives CytomX Therapeutics, Inc. a score of 45.

Our analysis is based on comparing CytomX Therapeutics, Inc. with the following peers – OncoMed Pharmaceuticals, Inc., Omeros Corporation, Onconova Therapeutics Inc. and Omni Bio Pharmaceutical, Inc. (OMED-US, OMER-US, ONTX-US and OMBP-US).

Investment Outlook

CytomX Therapeutics, Inc. has a fundamental score of 45 and has a relative valuation of OVERVALUED.

Fundamental Score

Access our research and ratings on CytomX Therapeutics, Inc.

Company Overview

  • From a peer analysis perspective, relative outperformance last month is up from a median performance last year.
  • CytomX Therapeutics, Inc.’s current Price/Book of 5.02 is about median in its peer group.
  • CTMX-US‘s earnings and EBITDA are both negative which suggest that P/E or Price/EBITDA are not meaningful to make this analysis between operating advantage (ROE) and growth expectations (as suggested by P/E or P/EBITDA).
  • CTMX-US‘s relatively low net margins and poor asset turns suggest a problematic operating strategy.
  • Changes in annual revenues are in line with its chosen peers but lags in terms of earnings suggesting that the company is less cost conscious and may be spending for growth.
  • CTMX-US‘s return on assets currently and over the past five years suggest that its relatively high operating returns are sustainable.
  • CTMX-US currently does not have any debt.

Access our research and ratings on CytomX Therapeutics, Inc.

Leverage & Liquidity

CTMX-US currently does not have any debt.

  • We consider the company to have a Quick & Able profile as it currently does not have any debt. In comparison, the median level of debt as percent of enterprise value for its peer group is currently 0%.
  • Of the 4 chosen peers for the company, only 2 of the stocks have an outstanding debt balance. Companies with no debt include OMED-US and ONTX-US.

Access the detailed analysis for CytomX Therapeutics, Inc.

Key Liquidity Items

Company Debt/Enterprise Value (%) Current Ratio Interest Coverage (x) Cash Flow To Total Debt (%)
OncoMed Pharmaceuticals, Inc. 0 3.83 No interest exp 999
Omeros Corporation 14.04 3.78 -9.79 -73.89
Onconova Therapeutics Inc. 0 3.1 No interest exp 999
Omni Bio Pharmaceutical, Inc. 19.05 0.58 -1.52 -72.44
CytomX Therapeutics, Inc. 0 7.74 -33.94 999
Peer Median 0 3.78 -1.52 999
Best In Class 14.04 7.74 No interest exp 999

Looking for more metrics and analysis for CytomX Therapeutics, Inc.?

Company Profile

CytomX Therapeutics, Inc. operates as an oncology-base biopharmaceutical company, which focuses on developing probody therapeutics for the treatment of cancer. The company was founded in September, 2010 and is headquartered in South San Francisco, CA.

Disclaimer

The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party’s use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any our reports, you’re agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website www.analytixinsight.com.